Brief by Shorts91 Newsdesk / 02:52pm on 02 May 2024,Thursday India
Bharat Biotech emphasizes Covaxin's safety record amidst AstraZeneca's acknowledgement of rare blood clot side effects. Covaxin, developed with a focus on safety and efficacy, underwent extensive trials and monitoring, with no reported vaccine-associated incidents. The statement follows AstraZeneca's admission of potential side effects. Covaxin, the only vaccine in India's immunization program with local efficacy trials, prioritizes patient safety. Bharat Biotech underscores ongoing safety monitoring and highlights its commitment to patient safety in vaccine development. Meanwhile, AstraZeneca faces a class-action lawsuit over alleged severe injuries and deaths related to its vaccine.
